Insider · CIK 0001688199

Read Simon

Reports to the SEC for 2 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001688199

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-19	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director	MExercise/Conversion	+2,778 sh	$18.36	+$51K	2,778
2026-08-19	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−2,778 sh	$117.55	−$327K	0
2026-08-19	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,778 sh	—	—	19,445
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	Director	MExercise/Conversion	+2,777 sh	$18.36	+$51K	2,777
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−70 sh	$107.11	−$7,497.7	2,707
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−737 sh	$108.17	−$79.7K	1,970
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−831 sh	$108.95	−$90.5K	1,139
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−272 sh	$109.96	−$29.9K	867
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−470 sh	$111.05	−$52.2K	397
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	Director	SSale	−397 sh	$111.77	−$44.4K	0
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,777 sh	—	—	22,223
2026-05-21	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director	AAward	+6,090 sh	—	—	6,090
2025-05-22	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2020-04-02	Ra Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−12.6K sh	$48.00	−$605K	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−46.4K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−26.4K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−25K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−67.5K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−55K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−107K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−9,166 sh	—	—	0
2019-12-17	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-12-17	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−10K sh	$47.08	−$471K	6,234
2019-12-17	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	46,142
2019-11-14	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-11-14	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−10K sh	$46.68	−$467K	6,234
2019-11-14	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	56,142
2019-10-16	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-10-16	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−10K sh	$46.87	−$469K	6,234
2019-10-16	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	66,142
2019-09-12	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-09-12	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−10K sh	$25.41	−$254K	6,234
2019-09-12	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	76,142
2019-08-23	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-08-23	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−10K sh	$27.77	−$278K	6,234
2019-08-23	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	86,142
2019-07-17	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-07-17	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−10K sh	$32.95	−$329K	6,234
2019-07-17	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	96,142
2019-06-18	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+10K sh	$2.87	+$28.7K	16,234
2019-06-18	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−9,586 sh	$22.21	−$213K	6,648
2019-06-18	Ra Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−414 sh	$23.09	−$9,559.508	6,234
2019-06-18	Ra Pharmaceuticals, Inc.Stock Options (Right to buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−10K sh	—	—	106,142
2019-02-01	Ra Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+9,167 sh	—	—	9,167
2019-02-01	Ra Pharmaceuticals, Inc.F Tax Payment	Chief Scientific Officer	FTax Payment	−2,933 sh	$21.00	−$61.6K	6,234
2019-02-01	Ra Pharmaceuticals, Inc.Options to Purchase Common StockA Award	Chief Scientific Officer	AAward	+107K sh	—	—	107,000
2019-02-01	Ra Pharmaceuticals, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−9,167 sh	—	—	18,333
2018-02-01	Ra Pharmaceuticals, Inc.Options to Purchase Common StockA Award	Chief Scientific Officer	AAward	+55K sh	—	—	55,000
2018-02-01	Ra Pharmaceuticals, Inc.Restricted Stock UnitA Award	Chief Scientific Officer	AAward	+27.5K sh	—	—	27,500
2017-02-01	Ra Pharmaceuticals, Inc.Options to Purchase Common StockA Award	Chief Scientific Officer	AAward	+67.5K sh	—	—	67,500

Recent filings

Accepted (ET)
Aug 194
Read Simon0001688199-26-000006
SEC(opens sec.gov)
Aug 114
Read Simon0001688199-26-000004
SEC(opens sec.gov)
May 224
Read Simon0001688199-26-000002
SEC(opens sec.gov)
May 224
Read Simon0000950170-25-076400
SEC(opens sec.gov)
Apr 34
Read Simon0001104659-20-042770
SEC(opens sec.gov)

Companies

Address

C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR

NEW YORK, NY, 10036